

Figure S2. Verification of signature prediction performance of the training group, test group and the entire group. (A-C) Curve plot of risk score, scatter plot of survival time, and heat map of expression values for 8 disulfidptosis-related long non-coding RNAs. (D-F) Visual representation of patients' risk scores across various survival statuses by scatterplot.




Figure S3. Additional validation of signature impacts. (A) Heat maps of 8 disulfidptosis-related long non-coding RNAs and clinical information. (B-E) Scatter plot analysis of risk score for patients with different clinical information.




Figure S4. Nomogram with patient verification.




Figure S5. (A) Bar and (B) circle diagrams for KEGG enrichment analysis. KEGG, Kyoto Encyclopedia of Genes and Genomes.




Figure S6. Gene set enrichment analysis. (A-C) High and (D) low risk group enrichment pathway in different gene sets. KEGG, Kyoto Encyclopedia of Genes and Genomes; GOBP, Gene Ontology Biological Process.




Figure S7. (A-D) Scatter plot of the correlation between 28 immune cells and risk score.




Figure S8. Efficacy evaluation of immunotherapy based on our signature. (A-D) Differences in (A) TIDE, (B) dysfunction, (C) exclusion and (D) microsatellite instability scores among different risk groups. *** $P < 0.001$ and **** $P < 0.0001$. TIDE, tumor immune dysfunction and exclusion; ns, not significant ($P > 0.05$).




Figure S9. Immunohistochemical staining images of portion disulfidptosis-related proteins in BLCA tissues and normal tissues. BLCA, bladder cancer.




Figure S10. (A-H) Expression levels and differences of 8 disulfidptosis-related long non-coding RNAs between different groups. * $P < 0.05$ and ** $P < 0.01$. ns, not significant ($P > 0.05$).




Figure S11. Expression levels and differences of 8 disulfidptosis-related long non-coding RNAs in normal bladder epithelial cell lines and BLCA cell lines (T24 and 5637 BLCA cell lines). * $P < 0.05$ and *** $P < 0.001$. BLCA, bladder cancer; ns, not significant ($P > 0.05$).




Figure S12. Bar charts of the expression levels of disulfidp-tosis-related genes in two cell lines from the Human Protein Atlas database.

